Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials
Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.
Product Name : Acetadote-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Kindeva Secures $129M SNS Contract for Nerve Agent Antidote
Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.
Product Name : Duodote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2025
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fennec Pharmaceuticals Announces NICE Positive Recommendation for Pedmarqsi®
Details : Pedmarqsi (anhydrous sodium thiosulfate) is the first and only intracellular oxidative stress inhibitor, treatment available in England for cisplatin-induced ototoxicity in 1 month-17 years of age.
Product Name : Pedmarqsi
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acetadote (N-acetylcysteine) is a FDA approved drug candidate, which is now being evaluated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen.
Product Name : Acetadote
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Gains FDA Nod for Pyridostigmine Bromide Extended-Release Tablets
Details : Pyridostigmine Bromide, is a cholinesterase inhibitor small molecule drug administered orally for soman nerve agent poisoning in adults.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Pyridostigmine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
MITEM Pharma Acquires DESFERAL® Rights Backed by TECHLIFE CAPITAL, MACSF
Details : Mitem acquires Desfera (deferoxamine mesylate) products from Novartis. It is indicated for treating iron overload, and forex, following blood transfusions necessary for treating beta-thalassemia.
Product Name : Desfera
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 25, 2024
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
M8 Pharmaceuticals Signs Exclusive Agreement with SERB to Bring Voraxaze® to Latin America
Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Product Name : DuoDote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Product Name : Edetate Calcium Disodium-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2023
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Actemra (tocilizumab) is designed to block the activity of IL-6, a type of inflammatory cytokine, which is indicated for the treatment of Cytokine Release Syndrome Induced by Cancer Therapy in Japan.
Product Name : Actemra
Product Type : Antibody
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Tocilizumab
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable